Inhibition of glycolate oxidase with dicer-substrate siRNA reduces calcium oxalate deposition in a mouse model of primary hyperoxaluria type 1

Primary Hyperoxaluria

Cochat, P., & Rumsby, G. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1301564 · Cited by 588 · see citing works

The primary hyperoxalurias

Höppe, B., Beck, B. B., & Milliner, D. S. (2009) · Kidney International · doi:10.1038/ki.2009.32 · Cited by 376 · see citing works

Peroxisomal alanine:glyoxylate aminotransferase deficiency in primary hyperoxaluria type I

Danpure, C. J., & Jennings, P. R. (1986) · FEBS Letters · doi:10.1016/0014-5793(86)80563-4 · Cited by 349 · see citing works

An update on primary hyperoxaluria

Höppe, B. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.113 · Cited by 313 · see citing works

The Primary Hyperoxalurias

Leumann, E., & Höppe, B. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1291986 · Cited by 228 · see citing works

Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1

Höppe, B., Beck, B. B., Gatter, N., von Unruh, G., Tischer, A., Hesse, A., Laube, N., Kaul, P., & Sidhu, H. (2006) · Kidney International · doi:10.1038/sj.ki.5001707 · Cited by 214 · see citing works

HISTOCHEMICAL IDENTIFICATION OF CALCIUM OXALATE

Yasue, T. (1969) · ACTA HISTOCHEMICA ET CYTOCHEMICA · doi:10.1267/ahc.2.83 · Cited by 197 · see citing works

Epidemiology of primary hyperoxaluria type 1

Cochat, P., Deloraine, A., Rotily, M., Olive, M. F., Liponski, I., Deries, N., & Pediatrique, O. B. O. T. S. D. N. A. T. S. D. N. (1995) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/10.supp8.3 · Cited by 186 · see citing works

Hydroxyproline ingestion and urinary oxalate and glycolate excretion

Knight, J. L., Jiang, J., Assimos, D. G., & Holmes, R. P. (2006) · Kidney International · doi:10.1038/sj.ki.5001906 · Cited by 160 · see citing works

Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization withOxalobacter

Hatch, M., Gjymishka, A., SALIDO, E. C., Allison, M. J., & Freel, R. W. (2010) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00434.2010 · Cited by 147 · see citing works

Primary hyperoxaluria type 1: still challenging!

Cochat, P., Liutkus, A., Fargue, S., Basmaison, O., Ranchin, B., & Rolland, M.-O. (2006) · Pediatric Nephrology · doi:10.1007/s00467-006-0124-4 · Cited by 146 · see citing works

Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria

Höppe, B., Groothoff, J. W., Hulton, S., Cochat, P., Niaudet, P., Kemper, M. J., Deschênes, G., Unwin, R. J., & Milliner, D. S. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr107 · Cited by 146 · see citing works

Vitamin B6 in Primary Hyperoxaluria I

Hoyer‐Kuhn, H., Kohbrok, S., Volland, R., Franklin, J. G., Hero, B., Beck, B. B., & Höppe, B. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06820613 · Cited by 138 · see citing works

Primary Hyperoxaluria

Harambat, J., Fargue, S., Bacchetta, J., Acquaviva, C., & Cochat, P. (2011) · International Journal of Nephrology · doi:10.4061/2011/864580 · Cited by 127 · see citing works

Alanine–glyoxylate aminotransferase-deficient mice, a model for primary hyperoxaluria that responds to adenoviral gene transfer

SALIDO, E. C., Li, X. M., Lu, Y., Wang, X., Santana, A., Roy‐Chowdhury, N., Torres, A., Shapiro, L. J., & Roy‐Chowdhury, J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607218103 · Cited by 125 · see citing works

The Roles and Mechanisms of Intestinal Oxalate Transport in Oxalate Homeostasis

Hatch, M., & Freel, R. W. (2008) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2008.01.007 · Cited by 86 · see citing works

Glycolate oxidase is a safe and efficient target for substrate reduction therapy in a mouse model of primary hyperoxaluria type I

Martin-Higueras, C., Luis-Lima, S., & Salido, E. (2016) · Molecular Therapy · doi:10.1038/mt.2015.224 · Cited by 83 · see citing works

Molecular aetiology of primary hyperoxaluria and its implications for clinical management

Danpure, C. J., & Rumsby, G. (2004) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399404007203 · Cited by 70 · see citing works

Mutations in HAO1 encoding glycolate oxidase cause isolated glycolic aciduria

Frishberg, Y., Zeharia, A., Lyakhovetsky, R., Bargal, R., & Belostotsky, R. (2014) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2014-102529 · Cited by 70 · see citing works

Hyperoxaluria Is Reduced and Nephrocalcinosis Prevented with an Oxalate-Degrading Enzyme in Mice with Hyperoxaluria

Grujić, D., SALIDO, E. C., Shenoy, B. C., Langman, C. B., McGrath, M. E., Patel, R. J., Rashid, A., Mandapati, S., Jung, C. W., & Margolin, A. L. (2008) · American Journal of Nephrology · doi:10.1159/000151395 · Cited by 67 · see citing works

Molecular Aetiology of Primary Hyperoxaluria Type 1

Danpure, C. J. (2004) · Nephron Experimental Nephrology · doi:10.1159/000080254 · Cited by 66 · see citing works

Pharmacologic rescue of an enzyme-trafficking defect in primary hyperoxaluria 1

Miyata, N., Steffen, J., Johnson, M. E., Fargue, S., Danpure, C. J., & Koehler, C. M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1408401111 · Cited by 61 · see citing works

Knockdown of β-catenin with Dicer-Substrate siRNAs Reduces Liver Tumor Burden In vivo

Dudek, H., Wong, D. H., Arvan, R., Shah, A., Wortham, K. A., Ying, B., Diwanji, R., Zhou, W. L., Holmes, B. R., Yang, H., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.233 · Cited by 56 · see citing works

Presentation and role of transplantation in adult patients with type 1 primary hyperoxaluria and the I244T AGXT mutation: Single-center experience

de Lorenzo, V., Alvarez, A., Torres, A., Torregrosa, V., Hernández, D., & SALIDO, E. C. (2006) · Kidney International · doi:10.1038/sj.ki.5001758 · Cited by 56 · see citing works

Oxalate removal by daily dialysis in a patient with primary hyperoxaluria type 1

Yamauchi, T., Quillard, M., TAKAHASHI, S. Y., & Man, N. K. (2001) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/16.12.2407 · Cited by 46 · see citing works

Hydroxyproline metabolism in mouse models of primary hyperoxaluria

Knight, J. L., Holmes, R. P., Cramer, S. D., Takayama, T., & SALIDO, E. C. (2011) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00473.2011 · Cited by 42 · see citing works

Treatment of the primary hyperoxalurias: A new chapter

Milliner, D. S. (2006) · Kidney International · doi:10.1038/sj.ki.5001821 · Cited by 26 · see citing works

Hyperoxalurie primitive

Cochat, P., Fargue, S., Bacchetta, J., Bertholet‐Thomas, A., Sabot, J.-F., & Harambat, J. (2011) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2011.03.004 · Cited by 19 · see citing works

Pharmacological approaches in the treatment of primary hyperoxaluria.

Holmes, R. P. (1998) · PubMed · Cited by 16 · see citing works

(L)‐2‐oxothiazolidine‐4‐carboxylate in the treatment of primary hyperoxaluria type 1

Holmes, R. P., Assimos, D. G., Wilson, D. M., & Milliner, D. S. (2001) · British Journal of Urology · doi:10.1046/j.1464-4096.2001.02439.x · Cited by 11 · see citing works

THE EFFECT OF (L)-CYSTEINE AND (L)-2-OXOTHIAZOLIDINE-4-CARBOXYLIC ACID (OTZ) ON URINARY OXALATE EXCRETION: STUDIES USING A HYPEROXALURIC RAT MODEL

BAKER, P. W., Rofe, A. M., & Bais, R. (1998) · The Journal of Urology · doi:10.1016/s0022-5347(01)63301-9 · Cited by 6 · see citing works

Gene Therapy Moves Forward in 2010

Ylä‐Herttuala, S. (2011) · Molecular Therapy · doi:10.1038/mt.2010.307 · Cited by 4 · see citing works

Therapeutic siRNA: State-of-the-Art and Future Perspectives

Friedrich, M., & Aigner, A. M. (2022) · BioDrugs · doi:10.1007/s40259-022-00549-3 · Cited by 413 · see citing works

RNAi therapeutic and its innovative biotechnological evolution

Weng, Y., Xiao, H., Zhang, J., Liang, X., & Huang, Y. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.04.012 · Cited by 288 · see citing works

An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria

Liebow, A., Li, X., Racie, T., Hettinger, J. L., Bettencourt, B. R., Najafian, N., Haslett, P. A. J., Fitzgerald, K. J., Holmes, R. P., Erbe, D. V., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016030338 · Cited by 200 · see citing works

Tapping the RNA world for therapeutics

Lieberman, J. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0054-4 · Cited by 195 · see citing works

Opportunities and challenges for antisense oligonucleotide therapies

Kuijper, E. C., Bergsma, A. J., Pijnappel, W. W. M. P., & Aartsma-Rus, A. M. (2020) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12251 · Cited by 156 · see citing works

Contribution of Dietary Oxalate and Oxalate Precursors to Urinary Oxalate Excretion

Crivelli, J. J., Mitchell, T., Knight, J. L., Wood, K. D., Assimos, D. G., Holmes, R. P., & Fargue, S. (2020) · Nutrients · doi:10.3390/nu13010062 · Cited by 107 · see citing works

Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria

Lai, C.-J., Pursell, N. W., Gierut, J. J., Saxena, U. H., Zhou, W. L., Dills, M., Diwanji, R., Dutta, C., Koser, M. L., Nazef, N., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.016 · Cited by 106 · see citing works

Extracellular vesicles versus lipid nanoparticles for the delivery of nucleic acids

Bader, J., Brigger, F., & Leroux, J. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115461 · Cited by 103 · see citing works

CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I

Zabaleta, N., Barberia, M., Martín-Higueras, C., Zapata‐Linares, N., Betancor, I., Rodríguez-Diaz, S., Martínez-Turrillas, R., Torella, L., Vales, Á., Olagüe, C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07827-1 · Cited by 86 · see citing works

Glycolate oxidase is a safe and efficient target for substrate reduction therapy in a mouse model of primary hyperoxaluria type I

Martin-Higueras, C., Luis-Lima, S., & Salido, E. (2016) · Molecular Therapy · doi:10.1038/mt.2015.224 · Cited by 83 · see citing works

Dietary Oxalate Intake and Kidney Outcomes

Bargagli, M., Tio, M. C., Waikar, S. S., & Ferraro, P. M. (2020) · Nutrients · doi:10.3390/nu12092673 · Cited by 83 · see citing works

RNA delivery biomaterials for the treatment of genetic and rare diseases

Zhao, W., Hou, X., Vick, O. G., & Dong, Y. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119291 · Cited by 82 · see citing works

Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1

Frishberg, Y., Deschênes, G., Groothoff, J. W., Hulton, S., Magen, D., Harambat, J., Hoff, W. V., Lorch, U., Milliner, D. S., Lieske, J. C., et al. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.14730920 · Cited by 82 · see citing works

RNA Therapeutics - Research and Clinical Advancements

Feng, R., Patil, S., Zhao, X., Miao, Z., & Qian, A. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.710738 · Cited by 73 · see citing works

Molecular basis of primary hyperoxaluria: clues to innovative treatments

Dindo, M., Conter, C., Oppici, E., Ceccarelli, V., Marinucci, L., & Cellini, B. (2018) · Urolithiasis · doi:10.1007/s00240-018-1089-z · Cited by 72 · see citing works

Hydroxyproline Metabolism and Oxalate Synthesis in Primary Hyperoxaluria

Fargue, S., Milliner, D. S., Knight, J. L., Olson, J. B., Lowther, W. T., & Holmes, R. P. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017040390 · Cited by 66 · see citing works

Characterising a healthy adult with a rare HAO1 knockout to support a therapeutic strategy for primary hyperoxaluria

McGregor, T. L., Hunt, K. A., Yee, E., Mason, D., Nioi, P., Ticau, S., Pelosi, M., Loken, P. R., Finer, S., Lawlor, D. A., et al. (2020) · eLife · doi:10.7554/elife.54363 · Cited by 57 · see citing works

Therapeutic RNA-silencing oligonucleotides in metabolic diseases

Goga, A., & Stoffel, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00407-5 · Cited by 58 · see citing works

Epigenomic and transcriptional profiling identifies impaired glyoxylate detoxification in NAFLD as a risk factor for hyperoxaluria

Gianmoena, K., Gasparoni, N., Jashari, A., Gabrys, P., Grgas, K., Ghallab, A., Nordström, K. J. V., Gasparoni, G., Reinders, J., Edlund, K., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109526 · Cited by 57 · see citing works

HAO1-mediated oxalate metabolism promotes lung pre-metastatic niche formation by inducing neutrophil extracellular traps

Zeng, Z., Xu, S., Wang, F., Peng, X., Zhang, W., Zhan, Y., Ding, Y., Liu, Z., & Li, L. (2022) · Oncogene · doi:10.1038/s41388-022-02248-3 · Cited by 50 · see citing works

The therapeutic prospects of N-acetylgalactosamine-siRNA conjugates

Zhang, L., Liang, Y., Liang, G., Tian, Z., Zhang, Y., Liu, Z., & Ji, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1090237 · Cited by 50 · see citing works

Recent advances in the identification and management of inherited hyperoxalurias

Sas, D. J., Harris, P. C., & Milliner, D. S. (2018) · Urolithiasis · doi:10.1007/s00240-018-1093-3 · Cited by 49 · see citing works

Improving Treatment Options for Primary Hyperoxaluria

Höppe, B., & Martín-Higueras, C. (2022) · Drugs · doi:10.1007/s40265-022-01735-x · Cited by 46 · see citing works

Molecular therapy of primary hyperoxaluria

Martín-Higueras, C., Torres, A., & Salido, E. (2017) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-017-0045-3 · Cited by 39 · see citing works

Advancing Therapeutic Strategies with Polymeric Drug Conjugates for Nucleic Acid Delivery and Treatment

Ullah, A., Khan, M., Zhang, Y., Shafiq, M., Ullah, M., Abbas, A., Xianxiang, X., Chen, G., & Diao, Y. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s429279 · Cited by 37 · see citing works

CRISPR/Cas9–mediated metabolic pathway reprogramming in a novel humanized rat model ameliorates primary hyperoxaluria type 1

Zheng, R., Li, Y., Wang, L., Fang, X., Zhang, J., He, L., Yang, L., Li, D., & Geng, H. (2020) · Kidney International · doi:10.1016/j.kint.2020.04.049 · Cited by 36 · see citing works

Genetic-Based Approaches to Inherited Metabolic Liver Diseases

Zabaleta, N., Hommel, M., Salas, D., & González‐Aseguinolaza, G. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.140 · Cited by 35 · see citing works

Knockdown of lactate dehydrogenase by adeno‐associated virus‐delivered CRISPR/Cas9 system alleviates primary hyperoxaluria type 1

Zheng, R., Fang, X., Chen, X., Huang, Y., Xu, G., He, L., Li, Y., Niu, X., Yang, L., Wang, L., et al. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.261 · Cited by 34 · see citing works

Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria

Forbes, T. A., Brown, B. D., & Lai, C.-J. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14925 · Cited by 32 · see citing works

Use of short interfering RNA delivered by cationic liposomes to enable efficient down-regulation of PTPN22 gene in human T lymphocytes

Perri, V., Pellegrino, M., Ceccacci, F., Scipioni, A., Petrini, S., Gianchecchi, E., Russo, A. L., Santis, S. D., Mancini, G., & Fierabracci, A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175784 · Cited by 30 · see citing works

The Ocular Phenotype in Primary Hyperoxaluria Type 1

Birtel, J., Herrmann, P., Garrelfs, S. F., Dulz, S., Atiskova, Y., Diederen, R. M. H., Gliem, M., Brinkert, F., Holz, F. G., Boon, C. J. F., et al. (2019) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2019.04.036 · Cited by 30 · see citing works

Salicylic Acid Derivatives Inhibit Oxalate Production in Mouse Hepatocytes with Primary Hyperoxaluria Type 1

Moya-Garzón, M. D., Martín-Higueras, C., Peñalver, P., Romera, M., Fernandes, M. X., Franco-Montalbán, F., Gómez-Vidal, J. A., SALIDO, E. C., & Díaz‐Gavilán, M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00399 · Cited by 29 · see citing works

Substrate reduction therapy for inborn errors of metabolism

Yue, W. W., MacKinnon, S., & Bezerra, G. A. (2019) · Emerging Topics in Life Sciences · doi:10.1042/etls20180058 · Cited by 29 · see citing works

Plasma Oxalate as a Predictor of Kidney Function Decline in a Primary Hyperoxaluria Cohort

Shah, R. J., Vaughan, L. E., Enders, F., Milliner, D. S., & Lieske, J. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103608 · Cited by 28 · see citing works

The primary hyperoxalurias: A practical approach to diagnosis and treatment

Hulton, S. (2016) · International Journal of Surgery · doi:10.1016/j.ijsu.2016.10.039 · Cited by 28 · see citing works

Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1

Torella, L., Klermund, J., Bilbao‐Arribas, M., Tamayo, I., Andrieux, G., Chmielewski, K. O., Vales, Á., Olagüe, C., Moreno, D., Raimondi, I., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-023-00008-8 · Cited by 27 · see citing works

Alteration of the gut microbiota by vinegar is associated with amelioration of hyperoxaluria-induced kidney injury

Zhu, W. J., Liu, Y., Duan, X., Xiao, C., Yu, L., Luo, L., Wu, C., Zhou, Y., Mai, X., Lu, S., et al. (2020) · Food & Function · doi:10.1039/c9fo02172h · Cited by 23 · see citing works

Investigational Therapies for Primary Hyperoxaluria

Kletzmayr, A., Ivarsson, M. E., & Leroux, J. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00268 · Cited by 23 · see citing works

In vivo CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria

Martínez-Turrillas, R., Martín-Mallo, Á., Rodríguez-Diaz, S., Zapata‐Linares, N., Rodríguez-Márquez, P., Martín‐Úriz, P. S., Vilas‐Zornoza, A., Calleja-Cervantes, M. E., SALIDO, E. C., Prósper, F., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.03.006 · Cited by 24 · see citing works

Lumasiran in the Management of Patients with Primary Hyperoxaluria Type 1: From Bench to Bedside

D’Ambrosio, V., & Ferraro, P. M. (2022) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s293682 · Cited by 23 · see citing works

Novel therapeutic approaches for the primary hyperoxalurias

Belostotsky, R., & Frishberg, Y. (2020) · Pediatric Nephrology · doi:10.1007/s00467-020-04817-8 · Cited by 22 · see citing works

Dual Glycolate Oxidase/Lactate Dehydrogenase A Inhibitors for Primary Hyperoxaluria

Ding, J., Gumpena, R., Boily, M.-O., Caron, A., Chong, O., Cox, J. H., Dumais, V., Gaudreault, S., Graff, A. H., King, A., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00196 · Cited by 22 · see citing works

Targeting kidney inflammation as a new therapy for primary hyperoxaluria?

Martín-Higueras, C., Ludwig‐Portugall, I., Höppe, B., & Kurts, C. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy239 · Cited by 22 · see citing works

Lipid‐based nucleic acid therapeutics with in vivo efficacy

Sufian, M. A., & Ilies, M. A. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1856 · Cited by 22 · see citing works

Efficacy of Hydroxy-L-proline (HYP) analogs in the treatment of primary hyperoxaluria in Drosophila Melanogaster

Yang, H., Male, M., Li, Y., Wang, N., Zhao, C., Jin, S., Hu, J., Chen, Z., Ye, Z., & Xu, H. (2018) · BMC Nephrology · doi:10.1186/s12882-018-0980-8 · Cited by 20 · see citing works

Primary hyperoxaluria diagnosed after kidney transplantation failure: lesson from 3 case reports and literature review

Cai, R., Lin, M., Chen, Z., Lai, Y., Huang, X., Zhao, G., Guo, X.-K., Xiong, Z., Chen, J., Chen, H., et al. (2019) · BMC Nephrology · doi:10.1186/s12882-019-1402-2 · Cited by 19 · see citing works

Glycolate oxidase deficiency in a patient with congenital hyperinsulinism and unexplained hyperoxaluria

Clifford-Mobley, O., Rumsby, G., Kanodia, S., Didi, M., Holt, R. C. L., & Senniappan, S. (2017) · Pediatric Nephrology · doi:10.1007/s00467-017-3741-1 · Cited by 19 · see citing works

Lactate dehydrogenase A inhibitors with a 2,8-dioxabicyclo[3.3.1]nonane scaffold: A contribution to molecular therapies for primary hyperoxalurias

Alejo‐Armijo, A., Cuadrado, C., Altarejos, J., Fernandes, M. X., SALIDO, E. C., Díaz‐Gavilán, M., & Salido, S. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106127 · Cited by 17 · see citing works

RNA nanotechnology: A new chapter in targeted therapy

Lv, T., Meng, Y., Liu, Y., Han, Y., Xin, H., Peng, X., & Huang, J. (2023) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2023.113533 · Cited by 17 · see citing works

Discovery of Novel, Potent Inhibitors of Hydroxy Acid Oxidase 1 (HAO1) Using DNA-Encoded Chemical Library Screening

Lee, E. C. Y., McRiner, A. J., Georgiadis, K. E., Liu, J. X., Wang, Z., Ferguson, A. D., Levin, B. D., von Rechenberg, M., Hupp, C. D., Monteiro, M. I., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02271 · Cited by 17 · see citing works

Lumasiran: expanding the treatment options for patients with primary hyperoxaluria type 1

Hulton, S. (2021) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2021.2003779 · Cited by 16 · see citing works

Multicenter Long-Term Real World Data on Treatment With Lumasiran in Patients With Primary Hyperoxaluria Type 1

Martín-Higueras, C., Borghese, L., Torres, A., Fraga-Bilbao, F., Santana‐Estupiñán, R., Stefanidis, C. J., Tory, K., Walli, A., Gondra, L., Kempf, C., et al. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.10.004 · Cited by 15 · see citing works

siRNA Therapeutics for Primary Hyperoxaluria: A Beginning

Milliner, D. S. (2016) · Molecular Therapy · doi:10.1038/mt.2016.50 · Cited by 15 · see citing works

Generation and characterization of a novel rat model of primary hyperoxaluria type 1 with a nonsense mutation in alanine-glyoxylate aminotransferase gene

Li, Y., Zheng, R., Xu, G., Huang, Y., Li, Y., Li, D., & Geng, H. (2021) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00514.2020 · Cited by 12 · see citing works

RNA interference in the treatment of renal stone disease: Current status and future potentials

Wood, K. D., Holmes, R. P., & Knight, J. L. (2016) · International Journal of Surgery · doi:10.1016/j.ijsu.2016.11.027 · Cited by 11 · see citing works

In Vivo siRNA Delivery and Rebound of Renal LRP2 in Mice

Eadon, M. T., Cheng, Y., Hato, T., Benson, E. A., Ipe, J., Collins, K. S., Luca, T. D., El‐Achkar, T. M., Bacallao, R. L., Skaar, T. C., et al. (2017) · Journal of Drug Delivery · doi:10.1155/2017/4070793 · Cited by 9 · see citing works

Effect of alanine supplementation on oxalate synthesis

Wood, K. D., Freeman, B. L., Killian, M. E., Lai, W. S., Assimos, D. G., Knight, J. L., & Fargue, S. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165981 · Cited by 9 · see citing works

Novel Starting Points for Human Glycolate Oxidase Inhibitors, Revealed by Crystallography-Based Fragment Screening

MacKinnon, S., Bezerra, G. A., Krojer, T. J., Szommer, T., von Delft, F., Brennan, P. E., & Yue, W. W. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.844598 · Cited by 8 · see citing works

Acetate attenuates hyperoxaluria-induced kidney injury by inhibiting macrophage infiltration via the miR-493-3p/MIF axis

Zhu, W., Wu, C., Zhou, Z., Zhang, G., Luo, L., Liu, Y., Huang, Z., Ai, G., Zhao, Z., Zhong, W., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-04649-w · Cited by 8 · see citing works

Emerging Approaches for Enabling RNAi Therapeutics

Mallick, A. M., Tripathi, A., Mishra, S., Mukherjee, A., Dutta, C., Chatterjee, A., & Roy, R. S. (2022) · Chemistry - An Asian Journal · doi:10.1002/asia.202200451 · Cited by 8 · see citing works

Treatment options in primary hyperoxaluria Type I

Cellini, B. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1298439 · Cited by 7 · see citing works

Small nucleic acid therapeutics: delivery breakthroughs, clinical translation, and future paradigms in precision medicine

Tang, Y., Zou, J., Li, Q., Liu, Y., Guo, X. D., Bai, H., He, X. D., Gan, C., Zhao, X., Wu, W., et al. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126189 · Cited by 6 · see citing works

Small Molecule-Based Enzyme Inhibitors in the Treatment of Primary Hyperoxalurias

Moya-Garzón, M. D., Gómez-Vidal, J. A., Alejo‐Armijo, A., Altarejos, J., Madoz, J. R. R., Fernandes, M. X., SALIDO, E. C., Salido, S., & Díaz‐Gavilán, M. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020074 · Cited by 5 · see citing works

From pathogenesis to novel therapies in primary hyperoxaluria

Rumsby, G., & Hulton, S. (2019) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2019.1571905 · Cited by 5 · see citing works

Generation of a mouse model of Primary Hyperoxaluria Type 1 via CRISPR/Cas9 mediated gene editing

Coughlan, K. A., Maganti, R. J., Frassetto, A., DeAntonis, C. M., Wolfrom, M., Graham, A.-R., Hillier, S., Fortucci, S., Jandal, H. A., Hong, S., et al. (2019) · Journal of Biochemical and Clinical Genetics · doi:10.24911/jbcgenetics/183-1542047633 · Cited by 5 · see citing works

Hao1 Is Not a Pathogenic Factor for Ectopic Ossifications but Functions to Regulate the TCA Cycle In Vivo

Kimura, A., Hirayama, A., Matsumoto, T., Sato, Y., Kobayashi, T., Ikeda, S., Maruyama, M., Kaneko, M., Shigeta, M., Ito, E., et al. (2022) · Metabolites · doi:10.3390/metabo12010082 · Cited by 4 · see citing works

Primary hyperoxaluria(s): from trials to real-life data and pipeline therapies

Bacchetta, J., Acquaviva, C., Abid, N., Leclerc, A.-L. S., Molin, A., & Lemoine, S. (2026) · Kidney International · doi:10.1016/j.kint.2025.12.029 · Cited by 3 · see citing works

Updated Gene Therapy for Renal Inborn Errors of Metabolism

Hergenrother, S. R., Husein, M., Thompson, C., Kalina, E., & Raina, R. (2025) · Genes · doi:10.3390/genes16050516 · Cited by 3 · see citing works

Primary Hyperoxaluria

Beck, B. B., & Höppe, B. (2016) · Springer eBooks · doi:10.1007/978-3-662-52972-0_39 · Cited by 3 · see citing works

siRNA Therapeutics to Treat Liver Disorders

Lai, C.-J., Martín-Higueras, C., & SALIDO, E. C. (2017) · Springer eBooks · doi:10.1007/978-3-319-53457-2_8 · Cited by 3 · see citing works

Néphrologie pédiatrique : que doit savoir un néphrologue d’adulte sur ces pathologies ?

Lemoine, S., Cochat, P., Bertholet‐Thomas, A., Levi, C., Bonnefoy, C., Leclerc, A.-L. S., & Bacchetta, J. (2017) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2017.01.025 · Cited by 2 · see citing works

Hereditary disorders of oxalate metabolism: The primary hyperoxalurias

Fargue, S., Milliner, D. S., & Danpure, C. J. (2020) · doi:10.1093/med/9780198746690.003.0237 · Cited by 1 · see citing works

Disorders of Oxalate Metabolism

Höppe, B., Beck, B. B., & Martín-Higueras, C. (2022) · Springer eBooks · doi:10.1007/978-3-030-67727-5_67 · Cited by 1 · see citing works

Patent Highlights June–July 2019

Mucke, H. A. (2019) · Pharmaceutical Patent Analyst · doi:10.4155/ppa-2019-0019

Vitamin B6-dependent enzymes and disease

Cellini, B., Betancor-Fernández, I., Grottelli, S., Fontana, N., Bellezza, I., & SALIDO, E. C. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819132-3.00010-5

Stratégies thérapeutiques pour l’application clinique des ARN interférents

Fattal, E. (2020) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2020.06.013

RNA interference in organ transplantation: next-generation medicine?

Brüggenwirth, I. M. A., & Martins, P. N. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819451-5.00008-1

Back to the Future: The Role of Metabolic Studies in Therapeutic Advances

Milliner, D. S., & Lieske, J. C. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021101325

Inherited Metabolic Disease and the Kidney

Gupta, A., Rumsby, G., & Hulton, S. (2022) · Springer eBooks · doi:10.1007/978-3-030-76419-7_64

Transfert de gènes dans les cellules souches pluripotentes induites : application à la thérapie génique de l'hyperoxalurie primitive de type 1

Estève, J. (2018) · doi:10.70675/2641738fzc780z4687zb2cdz783e1a783794

In Vivo Genome Editing Approach to Disrupt Hydroxyacid Oxidase 1 for the Treatment of Primary Hyperoxaluria Type 1

Greig, J. A., Breton, C. V. P., Smith, M. K., Furmanak, T., Bell, P. L., Clark, P., & Wilson, J. M. (2026) · Human Gene Therapy · doi:10.1177/10430342261460681

BindingDB Entry 50014995: Discovery of Novel, Potent Inhibitors of Hydroxy Acid Oxidase 1 (HAO1) Using DNA-Encoded Chemical Library Screening.

BindingDB (2023) · UC San Diego · doi:10.7270/q2cf9tzd

BindingDB Entry 50014135: Dual Glycolate Oxidase/Lactate Dehydrogenase A Inhibitors for Primary Hyperoxaluria.

BindingDB (2022) · UC San Diego · doi:10.7270/q2v128mv

BindingDB Entry 50002790: Salicylic Acid Derivatives Inhibit Oxalate Production in Mouse Hepatocytes with Primary Hyperoxaluria Type 1.

BindingDB (2020) · UC San Diego · doi:10.7270/q23b62sd

An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria

Liebow, A., Li, X., Racie, T., Hettinger, J. L., Bettencourt, B. R., Najafian, N., Haslett, P. A. J., Fitzgerald, K. J., Holmes, R. P., Erbe, D. V., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016030338 · Cited by 200 · see citing works

Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria

Lai, C.-J., Pursell, N. W., Gierut, J. J., Saxena, U. H., Zhou, W. L., Dills, M., Diwanji, R., Dutta, C., Koser, M. L., Nazef, N., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.016 · Cited by 106 · see citing works

Primary hyperoxaluria type 1: novel therapies at a glance

Bacchetta, J., & Lieske, J. C. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab245 · Cited by 41 · see citing works

Glycolate oxidase is a safe and efficient target for substrate reduction therapy in a mouse model of primary hyperoxaluria type I

Martin-Higueras, C., Luis-Lima, S., & Salido, E. (2016) · Molecular Therapy · doi:10.1038/mt.2015.224 · Cited by 83 · see citing works

Targeting Oxalate Production by Combining Enzyme Inhibition and Proteolysis Activation: A Novel Therapeutic Approach for Primary Hyperoxaluria Type 1

Arias, F., Rohilla, S., Sixto‐López, Y., Richard, K. S. E., Das, S., Anand, S. K., Luque-Navarro, P. M., Banuelos‐Sanchez, G., Pacheco‐García, J. L., Gade, R., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02055